Safety and Serum Virus Neutralizing Antibody Responses of VYD2311, a COVID-19 Vaccine, and Coadministered VYD2311 With a COVID-19 Vaccine
← catalyst calendarNCT07655180 · readout ≤ 12 d
Sponsored by Invivyd, Inc. (industry) · IVVD — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Triple · Prevention
Enrollment
210estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-06-08 | actual | When the study began enrolling |
| Primary completion | Aug 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Aug 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2026-06-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- COVID-19
Interventions
- Drug: COVID-19 mRNA vaccine
- Drug: VYD2311
- Drug: Placebo (Normal Saline)
Primary outcomes
what the primary-completion date above is the date OFAssessment of safety based on treatment emergent adverse events, injection site reactions, and hypersensitivity reactions through day 6
measured Through 6 days after dose
Assessment of systemic reactions solicited via e-diary through day 6
measured Through 6 days after dose
Permalink · IVVD's whole pipeline · Catalyst calendar · Every registered study · What changed